Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing

Citations Over TimeTop 1% of 2011 papers

Abstract

Warfarin is a widely used anticoagulant with a narrow therapeutic index and large interpatient variability in the dose required to achieve target anticoagulation. Common genetic variants in the cytochrome P450-2C9 (CYP2C9) and vitamin K-epoxide reductase complex (VKORC1) enzymes, in addition to known nongenetic factors, account for ~50% of warfarin dose variability. The purpose of this article is to assist in the interpretation and use of CYP2C9 and VKORC1 genotype data for estimating therapeutic warfarin dose to achieve an INR of 2-3, should genotype results be available to the clinician. The Clinical Pharmacogenetics Implementation Consortium (CPIC) of the National Institutes of Health Pharmacogenomics Research Network develops peer-reviewed gene-drug guidelines that are published and updated periodically on http://www.pharmgkb.org based on new developments in the field.(1).

Related Papers

• → Genetic Determinants of Response to Warfarin during Initial Anticoagulation(2008)580 cited
• Warfarin pharmacogenomics.(2009)
• → Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosingTest Category: Pharmacogenomic (Treatment)(2010)15 cited
• → Warfarin Dosing in a Patient withCYP2C9*3*3andVKORC1-1639 AAGenotypes(2014)9 cited
• → Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response(2010)8 cited